198 related articles for article (PubMed ID: 22086652)
21. Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1.
Yuan Z; Kumar EA; Kizhake S; Natarajan A
J Med Chem; 2011 Jun; 54(12):4264-8. PubMed ID: 21574625
[TBL] [Abstract][Full Text] [Related]
22. Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling.
Periasamy J; Kurdekar V; Jasti S; Nijaguna MB; Boggaram S; Hurakadli MA; Raina D; Kurup LM; Chintha C; Manjunath K; Goyal A; Sadasivam G; Bharatham K; Padigaru M; Potluri V; Venkitaraman AR
Cell Chem Biol; 2018 Jun; 25(6):677-690.e12. PubMed ID: 29606576
[TBL] [Abstract][Full Text] [Related]
23. Cancer-related mutations in BRCA1-BRCT cause long-range structural changes in protein-protein binding sites: a molecular dynamics study.
Gough CA; Gojobori T; Imanishi T
Proteins; 2007 Jan; 66(1):69-86. PubMed ID: 17063491
[TBL] [Abstract][Full Text] [Related]
24. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
[No Abstract] [Full Text] [Related]
25. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
Shiozaki EN; Gu L; Yan N; Shi Y
Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
[TBL] [Abstract][Full Text] [Related]
26. High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.
Lokesh GL; Rachamallu A; Kumar GD; Natarajan A
Anal Biochem; 2006 May; 352(1):135-41. PubMed ID: 16500609
[TBL] [Abstract][Full Text] [Related]
27. Cell signaling. The BRCT domain: signaling with friends?
Caldecott KW
Science; 2003 Oct; 302(5645):579-80. PubMed ID: 14576410
[No Abstract] [Full Text] [Related]
28. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.
Varma AK; Brown RS; Birrane G; Ladias JA
Biochemistry; 2005 Aug; 44(33):10941-6. PubMed ID: 16101277
[TBL] [Abstract][Full Text] [Related]
29. Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
Shen Y; Tong L
Biochemistry; 2008 May; 47(21):5767-73. PubMed ID: 18452305
[TBL] [Abstract][Full Text] [Related]
30. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
[TBL] [Abstract][Full Text] [Related]
31. Toward classification of BRCA1 missense variants using a biophysical approach.
Rowling PJ; Cook R; Itzhaki LS
J Biol Chem; 2010 Jun; 285(26):20080-7. PubMed ID: 20378548
[TBL] [Abstract][Full Text] [Related]
32. Cancer predisposing mutations in BRCT domains.
di Masi A; Gullotta F; Cappadonna V; Leboffe L; Ascenzi P
IUBMB Life; 2011 Jul; 63(7):503-12. PubMed ID: 21698754
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic insights into phosphopeptide--BRCT domain association: preorganization, flexibility, and phosphate recognition.
Huang YM; Kang M; Chang CE
J Phys Chem B; 2012 Aug; 116(34):10247-58. PubMed ID: 22857521
[TBL] [Abstract][Full Text] [Related]
35. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression.
Yu X; Wu LC; Bowcock AM; Aronheim A; Baer R
J Biol Chem; 1998 Sep; 273(39):25388-92. PubMed ID: 9738006
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
Dever SM; Golding SE; Rosenberg E; Adams BR; Idowu MO; Quillin JM; Valerie N; Xu B; Povirk LF; Valerie K
Aging (Albany NY); 2011 May; 3(5):515-32. PubMed ID: 21666281
[TBL] [Abstract][Full Text] [Related]
37. Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain.
White ER; Sun L; Ma Z; Beckta JM; Danzig BA; Hacker DE; Huie M; Williams DC; Edwards RA; Valerie K; Glover JN; Hartman MC
ACS Chem Biol; 2015 May; 10(5):1198-208. PubMed ID: 25654734
[TBL] [Abstract][Full Text] [Related]
38. Solution structure, backbone dynamics, and association behavior of the C-terminal BRCT domain from the breast cancer-associated protein BRCA1.
Gaiser OJ; Ball LJ; Schmieder P; Leitner D; Strauss H; Wahl M; Kühne R; Oschkinat H; Heinemann U
Biochemistry; 2004 Dec; 43(51):15983-95. PubMed ID: 15609993
[TBL] [Abstract][Full Text] [Related]
39. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
Williams RS; Glover JN
J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
[TBL] [Abstract][Full Text] [Related]
40. Interactions between BRCT repeats and phosphoproteins: tangled up in two.
Glover JN; Williams RS; Lee MS
Trends Biochem Sci; 2004 Nov; 29(11):579-85. PubMed ID: 15501676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
